New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 8, 2014
08:42 EDTKPTIKaryopharm warded grant from National MS Society
Karyopharm Therapeutics announced that it has been awarded a grant from the National Multiple Sclerosis, or MS, Society through its affiliate, Fast Forward, to support research on the potential of SINE compounds in inflammatory models of disease, including MS. Finding ways to restore and protect the damaged nervous system is a key priority of the National MS Society's No Opportunity Wasted research campaign to ultimately eradicate MS.
News For KPTI From The Last 14 Days
Check below for free stories on KPTI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
07:45 EDTKPTIKaryopharm initiates Phase 2 study of Selinexor
Karyopharm Therapeutics announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export, or SINE, compound Selinexor in patients with advanced gynecologic malignancies including cervical, ovarian and uterine carcinomas. In this Phase 2 study, patients will receive Selinexor at a dose of 50mg/m2, twice a week. The primary goal of the study is to determine the disease control rate assessed according to RECIST criteria. The secondary goal of the study is to evaluate safety and tolerability. Quality of life will also be evaluated.
April 21, 2014
07:06 EDTKPTIKaryopharm announces Phase 1 trial of Selinexor
Subscribe for More Information
April 15, 2014
16:08 EDTKPTIKaryopharm announces initiation of Phase 1 study of Selinexor-decitabine combo
Karyopharm Therapeutics announced the initiation of a Phase 1 combination trial of its novel, oral Selective Inhibitor of Nuclear Export compound Selinexor in combination with the DNA methylation inhibitor decitabine in patients with relapsed or refractory acute myeloid leukemia, or AML, and in patients age 60 years with newly diagnosed AML. Sharon Shacham, Karyopharm's founder, President and Chief Scientific Officer, commented, "This first combination study of Selinexor represents a significant milestone for the company as we look to broaden the scope of SINE compounds in the treatment of cancers."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use